Most Read

AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved

Under the deal, Mylan will acquire Aspen’s portfolio that includes injectable anticoagulants marketed in Europe under the brand names and variations of the brand names such as Arixtra,

The German company said that 41% of PAH patients transitioning to Adempas therapy after inadequate response to  phosphodiesterase-5 inhibitors (PDE5 inhibitors) achieved the composite primary endpoint, which is

Ibrutinib, a once-a-day drug that is administered orally, inhibits the first-in-class Bruton’s tyrosine kinase (BTK) that sends crucial signals to B cells to mature and produce antibodies, said

Alkahest is a clinical stage company that is focussed on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma

Gavreto, a once-daily and oral precision therapy, will help selectively target RET alterations such as fusions and mutations irrespective of the tissue of origin. Roche’s wholly-owned member Genentech

The FDA approval, which enables to expand the label of once-weekly Trulicity to include 3.0mg and 4.5mg doses, was based on data from the AWARD-11 phase 3 trial,

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

JTX-1811, which is a monoclonal antibody, is said to have been designed by Jounce Therapeutics to preferentially deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. The immunotherapy candidate’s target